KRAS mutations represent the most commonly encountered driver oncogene, implicated in approximately 25% of all human cancers, with KRASG12D emerging as a predominant isoform, particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. Despite its frequency, targeting KRASG12D poses distinct challenges due to the absence of a reactive amino acid residue for irreversible inhibitory modification by a ligand.
In pancreatic cancer, KRASG12D is detected in approximately 35% of cases, while in colorectal and non-small cell lung cancers, its prevalence stands at 13% and 5%, respectively. Although less common in other cancers, KRASG12D mutations remai...
